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1. Introduction 
Upper respiratory tract infection (URTI) is an acute infection involving nose, paranasal 
sinuses, pharynx, larynx, trachea, and bronchi. It is one of the commonest infectious disease 
affecting people of all age groups particularly children. In most of the cases it is of viral 
origin. Viruses like myxovirus, paramyxovirus, adenovirus, picornavirus, and coronavirus 
groups are some of the common viruses that cause cold and similar upper respiratory tract 
illnesses in adults (Hamre and Connelly, 1966; Mims et al., 1998). URTI are frequent as there 
are large numbers of different causative viruses and also re-infections may occur with the 
same type of virus because of its ability for antigenic drift/shift.  
There are many different antigenic types in these viruses and new strains/immunotypes are 
being discovered newly especially in coronavirus group. With the use of currently available 
methods of detection, the cause of approximately one third to one fourth of colds in adults 
remains unknown (Makela et al., 1998). Some illnesses may be undiagnosed because of the 
low sensitivity of diagnostic methods currently in use for detection of known viruses 
(Monto, 1997).  
The respiratory viruses have a worldwide distribution. An URTI epidemic usually tends to 
occur during rainy season in the tropics and colder months in the temperate regions. Some 
viruses have their own seasonality viz. rhinovirus infection has its peak in the autumn and 
coronaviruses in the winter. Apart from climate variation, relative humidity plays a vital 
role in survival of the viruses. Enveloped viruses survive better than non-enveloped virus in 
a low relative humidity (Gwaltney 1984). 
The main reservoir of respiratory viruses is the upper airway in young children. Spread of 
URTI is most common in an enclosed surrounding like home, schools and daycare centers 
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(Frenck RW, Glezen, 1990). The mechanisms for the spread of URTI viruses have not been 
well established but possibly occur by direct contact with infectious secretions on skin and 
environmental surfaces or contact with airborne droplet/droplet nuclei of respiratory 
secretions suspended in the environment or its combinations. For some viruses, such as 
rhinovirus and RSV, physical contact is necessary for efficient spread. Respiratory viruses 
are produced primarily in the nose and are shed in highest concentrations in nasal 
secretions. Effective spread is achieved when these viruses are present in hands of 
adults/children (Gwaltney, 1980). 
Bacterial origin of URTI is less common involving etiological agents such as beta-hemolytic 
streptococci, Corynebacterium diphtheriae, Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis (Richard and Garibaldi, 1985).  
2. Pathophysiology of RSV 
Respiratory syncytial virus (RSV) is an enveloped single-stranded RNA virus belonging to 
family Paramyxoviridae (genus Pneumovirus) and is related to the parainfluenza, mumps 
and measles virus. RSV is a highly infectious, ubiquitous and is one of the most contagious 
human pathogens, comparable to measles virus. The RSV outbreak was first documented in 
1964 in a neonatal intensive care unit (Berkovich, 1964). RSV is a significant cause of acute 
upper respiratory tract disease in individuals of all ages occurring both in normal and 
immunocompromised individuals (Hall et al., 2001).  
Globally, the World Health Organization (WHO, 2009) estimates that RSV causes 64 million 
infections and 160,000 deaths annually. Approximately two-thirds of infants are infected 
with RSV during the first year of life, and 90% have been infected one or more times by 2 
years of age (Karron et al., 1999). RSV infects patients earlier in life with greater 
consequences than other respiratory viruses. Rhinoviruses, influenza viruses, parainfluenza 
virus commonly infect children <6 months of age but RSV causes more frequent and severe 
infections because of their small size and narrow airways which is susceptible to 
obstruction. The ability to infect infants very early in life increases the impact of RSV.  
The risk factors for severe RSV (Welliver, 2003) 
 young age (<6 months) 
 premature birth (<35 weeks of gestation) 
 bronchopulmonary dysplasia 
 congenital heart disease 
 immunodeficiency or immunosuppression 
 low birth weight 
 low titer of RSV-specific serum antibodies 
 old age increased exposure to infection in day care center, hospitalization, multiple 
siblings  
 genetic predisposition (family history of asthma, genetic polymorphisms in genes 
encoding cytokines, chemokines)  
The two major strains of RSV are A and B. The A strain is responsible for the majority of 
more severe forms of RSV bronchiolitis (Martinello et al, 2002; Walsh et al, 1997). Martinello 
et al. (2002) found that a subgroup of the A strain (GA3) was associated with more severe 
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disease. It is also important to know that the different strains of RSV often circulate at the 
same time, and season-to-season variation is found in the predominant strain (American 
Academy of Pediatrics [AAP], 2003; Martinello et al., 2002). 
The virus is shed in nasopharyngeal secretions; infected patients can shed the virus for up to 
21 days. The portal of entry of the virus is through the mucosal surfaces of the mouth, nose, 
and conjunctivae. The virus replicates in the nasopharynx with an incubation period of 2 to 
8 days with replication cycle (in vitro) of 30 to 48 hours. G protein on the viral envelope 
mediates attachment of the virus to the superficial cells of the respiratory epithelium 
including type 1 pneumocytes in the alveoli which are major targets of infection in the lower 
airway and non-ciliated epithelium and intraepithelial dendritic cells (Beeler and van Wyke 
Coelingh, 1989) 
RSV invades the bronchiolar epithelial cells causing inflammation and edema. The 
membranes of the infected cells fuse with adjacent cells to form a large, multinucleated cell 
creating large masses of cells or "syncytia" (McIntosh, 2000; Wong et al., 2003) formation due 
to F (fusion) viral envelope glycoprotein which facilitates URTI to spread to lower 
respiratory tract. There may be occasional proliferation of the bronchiolar epithelium, 
infiltrates of monocytes and T cells centered on bronchiolar and pulmonary arterioles, and 
neutrophils between vascular structures and small airways. Infection and tissue damage are 
patchy rather than diffuse. There are abundant signs of airway obstruction due to sloughing 
of epithelial cells, mucus secretion, and accumulated immune cells (Levine et al., 1987). 
RSV URTI symptoms include coryza, cough, wheezing, low-grade fever (< 101°F), and 
loss of appetite. Symptoms of LTRI are common even in infants with mild disease. Clinical 
symptoms of bronchiolitis include increased airway resistance, air trapping, and 
wheezing. 
Coryza (the prominent symptom) is the inflammation of the mucous membranes lining the 
nasal cavity which causes nasal congestion and anosmia. The 3 stages of coryza are; 
 Dry Prodromal Stage (initial phase): nasal drying and irritation, low-grade fever, chills, 
general malaise, anorexia 
 Catarrhal Stage (second stage): watery clear rhinorrhea, congestion, lacrimation, 
worsening of constitutional symptoms 
 Mucous Stage: thickened rhinorrhea (greenish and foul smelling if secondarily 
infected), improved constitutional symptoms 
Reinfection with RSV occurs at all ages; however, with recurrent infection and increasing 
age, RSV infections are more limited to the URT. RSV URTI is more severe in nature than the 
URTI caused by other common cold viruses. RSV can re-infect throughout life without 
considerable antigenic change in sharp contrast with the ability of influenza A virus 
requiring antigenic drift or shift (Falsey et al., 2005). 
An uncomplicated URTI can also progress to complicated lower respiratory tract infection 
(LRTI). The pathogenesis of RSV-induced airway inflammation and hyperreactivity remain 
largely unknown. There is mounting evidence suggesting that young children who contract 
RSV infection are more likely to suffer from long-term respiratory complications like 
reactive airway disease later in life (Shaheen, 1995). It is also observed that severe infantile 
RSV and influenza virus LRT are characterized by inadequate adaptive immune responses. 
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There is no effective therapeutic option currently available for the management of acute and 
chronic clinical manifestations of RSV. 
3. Treatment of acute URTI 
Common cold is a self limiting illness and can resolve spontaneously. It has been rightly 
told that “treated cold lasts for 1 week and the untreated lasts for seven days”. The 
treatment of common cold is directed for alleviating the symptoms associated with it and 
the infection can be taken care by body’s own immunity 
Acute rhinosinusitis is most often associated with common cold and can be treated by a first 
generation antihistamine and a decongestant like pseudoephedrine. Similarly acute cough 
associated with common cold may be resolved by first generation antihistamine like 
diphenhydramine and chlorpheniramine along with decongestants (Chest 2006). Patients 
suffering from common cold are reluctant to take first generation antihistamines because of 
fear of drowsiness and absence from their work and can be treated by second generation 
antihistamine like cetirizine or loratadine for relief of symptoms of rhinosinusitis and acute 
cough. Cough usually occurs due to viral inflammation of the throat and can also be 
managed by simple home remedies like warm saline gargling and taking honey which can 
reduce symptoms and improve sleep particularly in children. Other drugs which can be 
prescribed for cough are dexomethorphan and codeine but these drugs can cause 
drowsiness and constipation respectively. 
Over the counter preparations for cough and cold has limited efficacy in relieving cough 
due to URTI (Braman 2006). They may have undesirable side effects like allergic reactions, 
sleep disturbances, hallucinations particularly in children and therefore they should be 
avoided in children. Rest is an important factor for treating URTI but usual activities such as 
working and light exercise may be advised as much as tolerated (Siamak, 2011). Increased 
intake of oral fluids is also encouraged to sustain the fluid loss from running nose, fever and 
poor appetite associated with URTI. (Siamak, 2011) 
Other medications which can be helpful in relieving the symptoms of common cold (acute 
URTI) are as follows 
 Acetaminophen or Paracetamol – It is a safe drug to be used in both adults and children 
to reduce fever and body ache which are often associated with acute URTI 
 NSAIDs – Non Steroidal Anti Inflammatory Drugs like ibuprofen can be used for fever 
and body ache  
 Nasal secretions can be reduced by using nasal ipratropium (topical) 
 Many cough medications like dextromethorphan, guaifenesin and codeine are also 
commercially available and can be used to relieve cough, if it is not reduced by saline 
gargling or antihistamines and decongestants. However, these medications can cause 
drowsiness and codeine can cause constipation.  
 Oxymetazolin nasal drops can be used to reduce nasal stuffiness but for a short period. 
It can cause after congestion. Very young children and infants may be relieved from 
nasal stuffiness by saline drops instilled into both the nostrils. 
 Other groups of drugs indicated are bronchodilators like short acting ǃ2agonists and 
ipratropium bromide administered by metered dose inhaler (MDIs) which help reduce 
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mucous in lungs and relax smooth muscles of large and medium bronchi, if URTI is 
associated with wheeze and bronchospasm. 
Antibiotics are not advised if the patient is otherwise healthy because the immune system 
can clear the viral infection. No benefit has been demonstrated in terms of overall 
improvement from the use of antibiotics compared to placebo in patients with acute URTI. 
(Arroll et al., 2008). 
Treatment with antibiotics neither shortens the duration of illness nor prevents bacterial 
rhinosinusitis and patients with purulent green or yellow secretions do not get benefit from 
antibiotic treatment (Gonzales et al., 2001) 
The following complications may need a course of antibiotics 
 Acute bacterial rhinosinusitis - Acute bacterial rhinosinusitis may develop in only 2% of 
cases (Hickner et al., 2001). Bacterial sinusitis may be present if symptoms persist for 
more than 7 days and pus is localized to the maxillary sinus (Hansen et al., 1995). 
Patients with mild symptoms need only symptomatic treatment with topical and oral 
decongestants. Patients with moderate or severe symptoms may be benefited by the use 
of narrow spectrum antibiotic like amoxicillin which can cover Streptococcus pneumoniae 
and Hemophilus influenzae. Alternatively Amoxicillin-clavalunic acid combination, third 
generation cephalosporins and for penicillin allergy, cotrimoxazole and extended 
spectrum macrolide or respiratory fluroquinolone may be considered if no 
improvement or worsening of symptoms after 72 hours. 
 Pharyngitis may occur due to infection by group A beta hemolytic streptococci 
(GABHS) and routine respiratory viruses. Antibiotics are indicated if the symptoms 
persist for more than 7 days or there is increased severity particularly with GABHS 
infection manifested by sore throat, fever, head ache, tonsilopharyngeal erythema and 
exudates, palatal petecheae and anterior cervical lymphadenopathy and absence of 
cough (Cooper et al., 2001). The diagnosis of GABHS may be confirmed by throat 
culture and rapid antigen testing before using antibiotics.  
First line therapy includes penicillin V or benzathine penicillin G 
Alternative therapy may be instituted by amoxicillin, oral cephalosporins and 
erythromycin incase of patients allergic to penicillin. 
Duration of treatment with suitable antibiotics is usually 10 days and the treatment 
guideline is same for adult as well as pediatric patients.  
 Otitis media in children – another indication for the use of antibiotics complicating 
URTI. In case of non severe illness, high dose of amoxicillin is the first line therapy. If 
this treatment fails, the combination of amoxycillin and clavulanic acid in high doses 
may be tried. Alternative therapy includes oral third generation cephalosporins and in 
penicillin allergic patients macrolides. Bacterial agents complicating URTI with  
 Acute bronchitis - Bacterial agents complicating are Bordetella pertussis, Mycoplasma 
pneumoniae and Chlamydia pneumoniae. Uncomplicated acute bacterial bronchitis does 
not need treatment with antibiotics even if the patient complains of purulent sputum. 
95% of patients with purulent sputum do not have pneumonia (Diehr et al., 1984). The 
evaluation and treatment of the patient should be focused on excluding severe illness 
particularly pneumonia (Metlay et al., 1997). Treatment with antibiotics is reserved for 
www.intechopen.com
 
Respiratory Diseases 
 
184 
patients having acute bacterial exacerbation of chronic bronchitis and COPD most often 
in smokers. Antibiotics preferred in this group are amoxicillin, cotrimoxazole or 
doxycycline. In case of B. pertussis, C. pneumoniae and M. pneumoniae erythromycin or 
doxycycline can be given. (Smucny et al., 2004).  
In children less than 8 years suffering from acute bronchitis and presenting with 
prolonged unimproving cough lasting for more than 14 days and after exclusion of 
pneumonia, macrolides may be preferred but for older children tetracyclines are 
preferable. Bronchiolitis or non specific URTI characterized by sore throat, sneezing, 
mild cough, fever less than 102ºF for less than 3days, rhinorrhea, nasal congestion, self 
limited typically 5-14days needs only symptomatic treatment with adequate fluid 
intake, rest and humidifier.  
URTI arising due to influenza and RSV needs special mention. The diagnosis of influenza 
may be done by abrupt onset of fever, myalgias, headache, rhinitis, severe malaise, non 
productive cough and sore throat. The mainstay of treatment is supportive care to relieve 
symptoms. But antiviral drugs like oseltamivir and zanamavir can decrease the duration of 
illness if administered within first 36hours of onset of illness (Montalto et al., 2000)  
Recently a number of studies have established RSV as a potential pathogen in certain adult 
population, particularly very elderly with underlying cardiopulmonary disease and 
immunocompromised individuals. But the disease remains undiagnosed in many situations 
because diagnosis is difficult during acute illness. Antibiotics may be used in selected RSV 
infected persons having bacterial pathogens isolated from their sputum. At present 
aerosolized ribavarin is the only approved treatment for RSV infection (AHRQ 2003, Falsy 
and Walsh 2000). But the use of ribavarin is controversial in case of infants and is indicated 
only in high risk patients. Two immunoglobulin preparations i.e., polyclonal high titred 
RSV immunoglobulin and a humanized F-specific monoclonal antibody can be used along 
with ribavarin. The treatment must be instituted promptly at the onset of the illness to 
effectively inhibit the replication of the virus. (Malhotra and Krilov 2000). But regular and 
wide spread use of immunoglobulins is not encouraging due to their high cost of each 
monthly dose and only high risk infants can get benefits from prophylactic treatment 
(Cooper , 2011). 
Development of RSV vaccine has been unsuccessful and previously developed vaccine 
using inactivated whole virus caused infection in infants. Recently it was understood that 
RSV can invade or even alter immune system. Therefore, better understanding of the 
immunological role of the virus and development of either immunomodulatory drugs or a 
vaccine remains the challenge for the future for the effective prevention or treatment of RSV 
infection (Sorrentino et al., 2000). 
4. A new strategy of management: Immunomodulation 
With the traditional knowledge available in the literature of the Siddha system of medicine 
(an ancient system of complementary medical practice in India) and the intense research on 
medicinal herbs done at Dr JRK Siddha Research and Pharmaceuticals Pvt Ltd, Chennai, 
India, a unique polyherbal formulation (trade named as SIVA syrup) was made with the 
following herbs. 
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Indigofera aspalathoides  
Celastrus paniculates  
Corallocarpus epigaeus  
Solanum trilobatum 
Wrightia tinctoria 
Bacoba monnieri 
Piper longum 
Piper nigrum 
Zingiber officinale 
Tinospora cordifolia 
Leucas aspera  
Piper betle 
5. Plant details  
Indigofera aspalathoides Vahl ex DC. (Papilionaceae) 
Vernacular names: Tamil – Shiva malli, shivanarvembu. 
Habit – Undershrubs, leaves digitately compound, flowers red, pods straight, turgid. 
Distribution – South India, Sri Lanka.  
Uses – Leaves, flower and tender shoots demulscent; their decoction used in cancerous 
lesions and leprosy. Leaves also applied in abscesses.  
Celastrus paniculatus Willd. (Celastraceae) 
Vernacular names: Sanskrit – Jyothismathi; Tamil – Vaaluluvai. 
Habit – Scandent shrubs with lenticellate branches. Leaves crenate-serrate. Flowers yellow 
or greenish-white, in terminal panicles. Capsules sub-globose, yellow with scarlet fleshy aril 
closing the seeds. 
Distribution – South Asia to Australia.  
Uses – Bark – Abortifacient. Seeds tonic and aphrodisiac. Seed oil used as nerve stimulant 
and brain tonic; also used in rheumatic pain.  
Chemical constituents – Plant contain sesquiterpene ester malkanguniol, malkangunin, 
celapanine, etc. and alkaloids celastrine and paniculatine. 
Corallocarpus epigaeus (Rottl. ex Willd.) Cl. (Cucurbitaceae) 
Vernacular names: Sanskrit – Shukanaasa; Tamil – Agasagarudan. 
Habit – Prostrate or climbing herb with tuberous roots. Leaves sub-orbicular. Flowers 
unisexual; female flowers usually solitary. Fruits ellipsoid, pulpy; seeds with a reddish 
margin. 
Distribution – Tropics.  
Uses – Roots used in chronic mucous enteritis and dysentery. It is also used as liniments for 
rheumatism.  
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Chemical constituents – Roots contains bitter principle bryonin. 
Solanum trilobatum Linn. (Solanaceae) 
Vernacular names: Sanskrit – ; Tamil – Thoothuvalai. 
Habit – Much branched spiny scandent shrubs. Leaves deltoid or triangular, irregularly 
lobed. Flower purplish blue, in cymes. Berry globose, red or scarlet. 
Distribution – Peninsular India and Malaysia.  
Uses – Roots used for consumption in the form of electuary, decoction or powder. Berries 
and flowers used to relief cough.  
Chemical constituents – Fruits and leaves contains alkaloid solasodine. 
Wrightia tinctoria (Roxb.) R.Br. (Apocynaceae) 
Vernacular names: Sanskrit – Svetakutaja; Tamil – Vetpalai. 
Habit – Small deciduous tree with light grey, smooth, scaly bark. Leaves elliptic-lanceolate. 
Flowers fragrant white, in lax, dichotomously branched terminal cymes. Follicle cylindrical, 
acute, cohering when young.  
Distribution – India, Sri Lanka.  
Uses – Bark and seeds used in flatulence and bilious troubles. Seed aphrodisiac and 
anthelmintic.  
Chemical constituents – Bark contains ǃ–sitosterol, ǂ- amyrin and its acetate and lupeol. 
Bacopa monnieri (L.) Penn. (Scrophulariaceae) 
Vernacular names: Sanskrit – Brahmi; Tamil – Neerbrahmi. 
Habit – Decumbent or creeping herbs rooting at nodes. Flowers solitary, bluish or 
pinkish.  
Distribution – Almost all districts in Tamilnadu, India and tropics.  
Uses – used in epilepsy, insanity and other nervous diseases. 
Chemical constituents – Plant contains nicotine, luteolin bacogenin A1, A2, A3, betulinic 
acid, bacoside A, A3, B & ǃ–sitosterol. 
Piper longum Linn. (Piperaceae) 
Vernacular names: Sanskrit – Pippali; Tamil – Thippili. 
Habit – Aromatic climbers with stout roots; stem jointed. Leaves ovate, cordate. Spikes 
cylindrical, peduncled. Fruits ovoid, yellowish-orange. 
Distribution – India, cultivated in many places.  
Uses – Roots and fruits used in respiratory tract diseases, as a counter irritant and analgesic 
for muscular pains and inflammations; as snuff in coma. 
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Chemical constituents – Roots contains alkaloids – piperlongumine, piperlonguminine, 
piperine, sesamine, piperolactum A & B. fruits yiels essential oil contains piperidine 
alkaloids, piperononaline, piperundecalidine etc. 
Piper nigrum Linn. (Piperaceae) 
Vernacular names: Sanskrit – Maricha; Tamil – Milagu. 
Habit – Much branched climbing shrub rooting at nodes. Leaves entire, cordate. Flowers 
minute in spikes. Fruit ovoid or globose, bright red when ripe. 
Distribution – south – west India, largely cultivated.  
Uses – fruits used in fever, anaemia, cough, diarrhoea, as stimulant, in weakness due to 
fever, as a stomachic, and malaria. Externally applied as rubefacient for sore throat, piles. 
Chemical constituents – Stem contains sesquisabinene , piperine, hentriacontane,  
ǃ–sitosterol. Fruits contains piperine, oleoresin and volatile oil. 
Zingiber officinale Rosc. (Zingiberaceae) 
Vernacular names: Sanskrit – Sunthi; Tamil – Inji. 
Habit – Slender aromatic rhizomatous herbs with leafy stem. Leaves linear-lanceolate, 
distichous, subsessile. Flowers greenish-yellow with dark purple or purplish black tip, in 
spikes. 
Distribution – Extensively cultivated in many places all over the world.  
Uses – Carminative and stimulant and also given in flatulence and colic. 
Chemical constituents – Rhizomes contains diarylheptanoids, essential oil, zingiberene, 
zingiberenol, sesqui-thujene, cumene, myrcene, limonene, gingerol, shagoal, zingerone and 
paradol. 
Tinospora cordifolia (Wild.)Hk.f. & Th. (Menispermaceae) 
Vernacular names: Sanskrit – Guduchi; Tamil – Seenthilkodi. 
Habit – Large climbing shrubs; bark greyish-brown or creamy-white, warty. Leaves 
membranous broadly ovate, cordate at base. Flowers greenish-yellow, appearing when the 
plant is leafless, in axillary and terminal racemes or panicles. Drupe ovoid, shining, 
succulent, light red when ripe. 
Distribution – India, Srilanka.  
Uses – Stem is an ingredient of several ayurvedic preparations used in general debility, 
dyspepsia, fever and urinary diseases. Leaf decoction given in gout. 
Chemical constituents –Plant containe quaternary alkaloids – magnoflorine, tembestarine 
and isoquinoline alkaloid – jatrorrizine, furanoid diterpene, clerodane, tinosporidine, 
tinosporoside etc. 
Leucas aspera (Wild.) Link (Lamiaceae) 
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Vernacular names: Sanskrit – Dronapushpi; Tamil – Thumbai. 
Habit – Erect herbs with diffuse quadrangular branches. Leaves linear-lanceolate. Flowers 
white, in verticils. Nutlets oblong. 
Distribution – India and Malaysia.  
Uses – Juice of leaves applied externally in psoriasis, chronic skin eruptions and painful 
swellings. Flowers given with honey in coughs and cold. 
Chemical constituents – plant contains sterol, alkaloids, galactose, oleanolic acid, ursolic 
acid etc. 
Piper betle Linn. (Piperaceae) 
Vernacular names: Sanskrit – Tambulavalli; Tamil – Vettrilai. 
Habit – woody climber with adventitious roots. Leaves broadly ovate, slightly cordate and 
often obliqual at base. Male flowers in dense spike; female spikes pendulous. Fruits black in 
the fleshy spike. 
Distribution – Native of Malaysia, cultivated in india.  
Uses – decoction of leaves used for healing wounds. Roots with black pepper used to 
produce sterility in woman. Leaves yield essential oil which is used in repiratory catarrh 
and diphtheria, also as a carminative. 
Chemical constituents – Leaves contains iodine, vitamin B, essential oil contains – 
chavibetol, chavibetol acetate, caryophyllene, allylpyrocatechol, camphene, eugenol etc.  
These plants possess properties to modulate the immune system by induction, expression, 
amplification or inhibition of any part or phase of the immune response. Plants like Solanum 
trilobatum, Wrightia tinctoria, Tinospora cordifolia and Leucas aspera has been extensively used 
in Siddha preparations. Crude extracts of these plants possess wide range of properties like 
increase in total WBC count, boosting the phagocytic index of macrophages, polyclonal B 
cell activation, increase secretion of Interleukin-1 and tumor necrosis factor (TNF). 
Immunomodulation through plants provide inexpensive, safe, viable and natural means of 
seeking an effective alternate treatment.  
6. Study methods 
6.1 Virus preparation and assay 
High-titer stocks of RSV were prepared on HEp2 cell monolayers. Virus titers were 
determined by plaque assay on STAT1_/_ mouse fibroblasts. Equivalent number of 
plaques was counted on STAT1_/_ fibroblast and HEp2 monolayers, but they appeared 
much more rapidly on the knockout murine cells: 36 h versus 5 days, respectively (Gitiban 
et al, 2005).  
6.2 Study animals and infection 
Juvenile chinchillas (Chinchilla lanigera) 3 months of age and weighing 300 to 350 g, were 
used. Male and female BALB/c mice were also used for the study. Mice were infected i.n. 
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following methodologies that were developed to deliver an inoculum specifically to the 
upper airway using a very small volume (Johnson et al., 1996, Visweswaraiah et al., 2002). 
Briefly, each mouse was mildly anesthetized, placed in a supine position, and given 103 PFU 
of RSV in a 20-μl volume. Two microliters per naris were delivered at 0, 2, 7, 9, and 11 min. 
Chinchillas were also inoculated i.n. with RSV, again delivered specifically to the upper 
airway. The dosages (in total PFU delivered), 103 were administered by passive inhalation of 
droplets of viral suspension delivered to the nares of chinchillas that were lightly 
anesthetized with xylazine (2mg/kg of body weight) and were lying in a prone position. 
(Gitiban et al, 2005).  
6.3 Treatment with polyherbal formulation 
The feed and water were provided to the animals ad libitum. The animals were grouped into 
two groups of 3 animals each as polyherbal formulation treated and non treated control. 
However, both groups were infected with RSV. The animals were infected only after 10 days 
of treatment with polyherbal formulation. After 5 days of infection, the animals from both 
groups were euthanized and the visceral regions were examined to assess the rate of 
infection.  
6.4 Lavages and recovery of tissues for quantitative viral  
culture  
RSV-infected mice under treatment and control groups were sacrificed at various time 
points by CO2 inhalation. For virus titration, lungs and nasal mucosa were immediately 
frozen in liquid nitrogen. Prior to plaque assay, tissues were weighed and homogenized in 1 
ml phosphate-buffered saline (PBS). Tissue homogenates were assayed as described above 
(Gitiban et al, 2005).  
6.5 Serum neutralization assay  
RSV (500 PFU/ml) was mixed with serial dilutions of chinchilla serum and incubated at 
room temperature for 30 min. These mixtures (100μl) were used to inoculate confluent 
monolayers of mouse STAT1_/_ fibroblast cells grown in 24-well plates. After 1-h 
incubation at 37°C, infected cells were washed and fed with growth medium plus 0.5% 
methylcellulose. After 2 days, plates were stained with crystal violet and plaques counted. 
The neutralizing titer was defined as the serum dilution that resulted in  
50% reduction in plaque number compared to controls that had no serum (Gitiban et al, 
2005).  
7. Histology study 
Sections through the NP of mice were obtained following formalin fixation and 
decalcification. For immunohistochemistry, sections were blocked with a Vector 
Avidin/Biotin blocking kit. Sections were visualized using a biotinylated mouse anti-goat 
secondary antibody, streptavidin-horseradish peroxidase, the chromogen AEC and a 
hematoxylin counterstaining. 
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8. Predisposition of Chinchilla to infection of the upper airway with  
RSV following i.n. challenge  
A dose-effect was clearly detectable in chinchillas inoculated with increasing doses of RSV. 
At the lower dosages assayed, no signs of illness were noted at any time of post challenge. 
Conversely, animals that received higher dosages of the virus without polyherbal 
formulation treatment showed signs of acute respiratory tract infection. The symptoms of 
viral infection like ruffling of fur and lethargic behavior were observed by day 3-4 after 
challenge in all the animals that did not receive pre-treatment with polyherbal formulation.  
In addition, nasal lavage fluids recovered from the RSV-infected chinchillas (control) had an 
abnormal yellowish-green tint and was notably turbid. There was no such change observed 
in polyherbal formulation treated group of animals. This latter observation is consistent 
with histopathological evaluations that showed hypersecretion of mucus into the ET lumen 
in tissues recovered from untreated chinchillas; such change was not seen in the case of 
polyherbal formulation treated group. Plaque assays conducted with homogenized NP 
mucosa and NP lavage fluids indicated that the chinchilla was permissive to RSV infection. 
Both NP mucosal tissue homogenates and NP lavage fluid specimens were positive on days 
4 and 8 after challenge. Preliminary evidence in support of restriction of viral replication to 
the uppermost airway following i.n. challenge was supported by the absence of viral 
plaques when tracheal mucosa and lung tissue recovered 4 days after challenge in the 
treatment group even after receiving highest dose of RSV. This clearly indicates that the 
polyherbal formulation pretreatment prevent viral multiplication within 4 day of challenge. 
9. RSV infection results in goblet cell hyperplasia, hypersecretion of mucus, 
and the clear presence of RSV within cells lining the ET  
Examination of NP and ET mucosae from control animals showed the presence of mild 
inflammation. Periodic acid-Schiff–Alcian Blue staining showed sparse mononuclear 
submucosal infiltrate with eosinophils, marked goblet cell hyperplasia with mucus 
hypersecretion into the lumen of the ET. However no such abnormalities were observed in 
the polyherbal formulation treated animals. The relative abundance of mucus in the ET 
lumen, the number of heavily stained goblet cells, and the intensity of staining of 
submucosal glands in an RSV-infected chinchilla treated vs untreated with polyherbal 
formulation was observed. Clear distinction in the histological findings in the treated and 
control group was seen. 
10. Conclusion 
RSV is the chief cause of most of the upper respiratory infections in human being. The focus 
of the present study was to evaluate the immunomodulatory effect of polyherbal 
formulation (SIVA syrup) against RSV infection in animal model. Immunomodulatory 
potential of medicinal plants have been extensively studied by several researchers. (Benny et 
al., 2004; Kripa et al., 2011; Sunila & Kuttan, 2004). We have established the 
immunoprotective/immunomodulating effect can be achieved using polyherbal 
formulation earlier in our studies (Ranjith et al., 2010). Polyherbal formulation increases the 
phagocytosis index to several times over control when tested against murine phagocytes in 
vitro (Ranjith et al., 2008). Further, the effect of polyherbal formulation on the humoral 
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antibody production in animal model by using SRBC as an antigen was also established 
(Ranjith, 2009). Candidal infections are quite common when the first line of host’s defence 
mechanism get abrogated. Revalidation of the immune protection effect of polyherbal 
formulation in preventing experimental candidal infection in animal model was also 
confirmed (Ranjith, 2009). Findings of all the above studies clearly suggest that polyherbal 
formulation of medicinal plants is a very potent immunomodulator and has a significant 
role in the health and well being.  
Several compliments have been received from various practitioners of alternative medicines 
in India for the role of SIVA in the management of upper respiratory tract infections 
especially in children, particularly of viral origin. The present study clearly established that 
polyherbal formulation has very specific effect of immune protection against upper 
respiratory tract infection caused by RSV in animal model. Comparative viral and 
hematological examinations of pretreated and control animals reveal that polyherbal 
formulation offers strong protection against RSV infection.  
One of the plant compounds in the polyherbal formulation is Indigofera asphalathoides which 
is extremely bitter in taste. Most of the bitter principles viz., Azadirachta indica, Phyllanthus 
niruri, Terminalia chebula are known to have high antiviral activity. Further the therapeutic 
role of the bitter fraction in the bitter-gourd is also well known. The use of the bitter plant – 
Indigofera aspalathoides in the traditional drug preparations date back to Siddha era which is 
around 2000 BC. In the recent years, modern science has proved the role of bitter principles 
and bitter yielding plants have high therapeutic value including antiviral activity.  
The exact mode of action of polyherbal formulation on RSV is not clearly understood. 
However, the protection of the polyherbal formulation treated group against the RSV 
infection could be attributed to its antiviral and immunomodulatory properties of the 
constituent medicinal plants in the formulation. A detailed clinical study is inevitable to 
substantiate the antiviral and immunomodulatory effect of the polyherbal formulation. 
Nevertheless immunomodulation would be the futuristic approach for the management of 
upper respiratory viral infections. 
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